Target intelligence / Profile preview

Enteric nervous system (ENS) and colonic mucosa (ENS)

Target
ENS
Molecular classification
Other
01

Overview

The colonic mucosa and enteric neural apparatus (ENA) represent the integrated physiological system of the large intestine responsible for regulating motility, secretion, and barrier function (Furness, 2012). The ENA, specifically the enteric nervous system (ENS), consists of the myenteric and submucosal plexuses, which contain a vast network of neurons and glia that coordinate peristalsis and local blood flow independently of the central nervous system (Gershon, 1999). The colonic mucosa acts as a critical interface for water absorption and immune surveillance, with its functions tightly regulated by neurotransmitters released from the underlying neural network (Sharkey & Savidge, 2014). This complex tissue system is the site of action for various drugs, such as 5-HT4 agonists (e.g., prucalopride) and guanylate cyclase-C activators (e.g., linaclotide), which are used to treat functional gastrointestinal disorders like chronic idiopathic constipation and irritable bowel syndrome (Rao & Camilleri, 2010). Dysregulation of this apparatus is central to the pathogenesis of conditions such as Hirschsprung disease, where the neural plexuses are absent, and inflammatory bowel disease, where mucosal integrity is compromised (Costa et al., 2000). Because this term describes a multi-component anatomical region rather than a single protein or receptor, it is classified as a biological system rather than a discrete molecular therapeutic target.

Other names
Enteric nervous systemENSIntrinsic nervous systemMyenteric plexusSubmucosal plexusColonic neural networkGut-brain axis (local component)
02

Mechanism of action

Modulation of enteric neurotransmission and mucosal ion transport via activation or inhibition of specific receptors (e.g., 5-HT4, GC-C, mu-opioid) to alter intestinal motility and fluid secretion.

03

Biological functions

Signal transductionImmune responseOther
04

Disease associations

InflammationOther
05

Safety considerations

Ischemic colitisSevere diarrheaElectrolyte imbalanceBowel obstructionCardiovascular risks (class-specific)
06

Interacting drugs

Prucalopride

7 more in the full profile.

07

Biomarkers

Fecal calprotectinColonic transit timeEnteric glial fibrillary acidic protein (GFAP)Vasoactive intestinal peptide (VIP) levels

Beyond the preview

Go deeper on Enteric nervous system (ENS) and colonic mucosa (ENS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enteric nervous system (ENS) and colonic mucosa (ENS).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call